Structural characterization of recombinant therapeutic proteins by circular dichroism

Current Pharmaceutical Biotechnology

Volumn 12, Issue 10, 2011, Pages 1508-1516

  Bertucci, Carlo ^a   Pistolozzi, Marco ^a   de Simone, Angela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aggregation; Bioavailability; Circular dichroism; Protein formulation; Quality control; Recombinant protein therapeutics; Thermal stability

Indexed keywords

ALGINIC ACID; ANTIDIABETIC AGENT; BOVINE INSULIN; CARBOXYMETHYLCELLULOSE; CHITOSAN; ENFUVIRTIDE; FUZEO; HUMAN INSULIN; HYDROXYPROPYLMETHYLCELLULOSE; MMA 383; MMA 383 ANTIBODY; MONOCLONAL ANTIBODY; NANOPARTICLE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT HIRUDIN; RECOMBINANT HUMAN INSULIN; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; REGULAR ILETIN I; RIBAVIRIN; RITUXIMAB; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; B CELL LEUKEMIA; B CELL LYMPHOMA; CIRCULAR DICHROISM; DERIVATIZATION; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG STORAGE; ENZYME ACTIVITY; HAIRY CELL LEUKEMIA; HEPATITIS C; KAPOSI SARCOMA; NONHODGKIN LYMPHOMA; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN STRUCTURE; STEREOCHEMISTRY;

ANIMALIA;

EID: 80052384645     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798357276     Document Type: Article

References (50)

1. Leader, B.; Baca, Q.J.; Golan, D.E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov., 2008, 7, 21-39.
2. Tomlinson, I. M. Next-generation protein drugs. Nat. Biotechnol., 2004, 22, 521-522.
3. Chirino A.J.; Mire-Sluis, A. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol., 2004, 22, 1383-1391.
4. Lee Whitmore, L.; Wallace, B. A. Protein secondary structure analyses from circular dichroism spectroscopy: Methods and reference databases. Biopolymers, 2007, 89, 392-400.
5. Nakanishi, K.; Berova, N.; Woody, R.W. Circular dichroism, principles and applications. VCH Publishers. New York, 1994.
6. Bijvoet, J.M.; Peerdeman, A.F.; van Bommel, A.J. Determination of the absolute configuration of optically active compounds by means of Xrays. Nature, 1951, 168, 271-272.
7. Flack, H.D. On enantiomorph-polarity estimation. Acta Crystallogr A, 1983, 39, 876-881.
8. Chang, C. T.; Wu, C. S.; Yang, J. T. Circular dichroic analysis of protein conformation: inclusion of the beta-turns. Anal. Biochem., 1978, 91, 13-31.
9. Wüthrich, K. The way to NMR structures of proteins. Nat. Struct. Biol., 2001, 8, 923-925.
10. Pellecchia, M.; Bertini, I.; Cowburn, D.; Dalvit, C.; Giralt, E.; Jahnke, W.; James, T.L.; Homans, S.W.; Kessler, H.; Luchinat, C.; Meyer, B.; Oschkinat, H.; Peng, J.; Schwalbe, H.; Siegal, G. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discov., 2008, 7, 738-745.
11. Wallace, B. A.; Teeters, C. L. Differential absorption flattening optical effects are significant in the circular dichroism spectra of large membrane fragments. Biochemistry, 1987, 26, 65-70.
12. Compton, L. A.; Johnson, W. C. Jr. Analysis of protein circular dichroism spectra for secondary structure using a simple matrix multiplication. Anal. Biochem., 1986, 155, 155-167.
13. Provencher, S. W.; Glockner, J. Estimation of globular protein secondary structure from circular dichroism. Biochemistry, 1981, 20, 33-37.
14. Sreerama, N.; Woody, R. W. A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal. Biochem., 1993, 209, 32-44.
15. Perczel, A.; Park, K.; Fasman, G. D. Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: a practical guide. Anal. Biochem., 1992, 203, 83-93.
16. Pancoska, P.; Janota, V.; Keiderling, T. A. Novel matrix descriptor for secondary structure segments in proteins: demonstration of predictability from circular dichroism spectra. Anal. Biochem., 1999, 267, 72-83.
17. Böhm, G.; Muhr, R.; Jaenicke, R. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng., 1992, 5, 191-195.
18. Andrade, M. A.; Chacón, P.; Merelo, J. J.; Morán, F. Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng., 1993, 6, 383-390.
19. Lees, J. G.; Miles, A. J.; Janes, R. W.; Wallace, B. A. Novel methods for secondary structure determination using low wavelength (VUV) circular dichroism spectroscopic data. BMC Bioinformatics, 2006, 7, 507-516.
20. Bertucci C.; Pistololozzi, M.; De Simone, A. Circular dichroism in drug discovery and development: an abridged review. Anal. Bioanal. Chem., 2010, 398, 155-166.
21. Imai N.; Kawamura A.; Higuchi M.; Oh-eda M.; Orita T.; Kawaguchi T.; Ochi N. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J. Biochem., 1990, 107, 352-359.
22. Quadrifoglio, F., Urry, D.W., Circular dichroism and optical rotatory dispersion of gramicidin S in acqueous solution. Biochem. Biophys. Res. Commun., 1967, 29, 785-791.
23. Beychok, S.; Breslow, E. Circular dichroism of oxytocin and several oxytocin analogues. J. Biol. Chem., 1968, 243, 151-154.
24. Melberg, S.G.; Johnson, W.C. Jr. Changes in secondary structure follow the dissociation of human insulin hexamers: a circular dichroism study. Proteins, 1990, 8, 280-286.
25. Johnson I.S. The trials and tribulations of producing the first genetically engineered drug. Nat. Rev. Drug Discov., 2003, 2, 747-751.
26. Sarmento, B.; Ferreira, D.C.; Jorgensen, L.; van de Weert, M. Probing insulin's secondary structure after entrapment into alginate/ chitosan nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 65, 10-17.
27. Khafagy, E.; Morishita, M.; Onuki, Y.; Takayama, K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev., 2007, 59, 1521-1546.
28. Amidi, M.; Hubert C. Pellikaan, H.C.; de Boer, A.H.; Crommelin, D.J.A.; Hennink, W.E.; Jiskoot, W. Preparation and physicochemical characterization of supercritically dried insulin-loaded microparticles for pulmonary delivery. Euro. J. Pharm. Biopharm., 2008, 68, 191-200.
29. Yong, Z.; Yingjie, D.; Xueli, W.; Jinghua, X.; Zhengqiang, L. Conformational and bioactivity analysis of insulin: Freeze-drying TBA/water co-solvent system in the presence of surfactant and sugar. Intl. J. Pharm., 2009, 371, 71-81
30. Nielsen L.; Frokjaer S.; Brange J.; Uversky V.N.; Fink A.L. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry, 2001, 40, 8397-8409.
31. Nielsen L.; Khurana R.; Coats A.; Frokjaer S.; Brange J.; Vyas S.; Uversky V.N.; Fink A.L. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry, 2001, 40, 6036-6046.
32. Rui L.; Mingxia H.; Rongxin S.; Yanjun Y.; Wei Q.; Zhimin H. Insulin amyloid fibrillation studied by terahertz spectroscopy and other biophysical methods. Biochem. Biophys. Res. Commun., 2010, 391, 892-897.
33. Loksztejn, A.; Dzwolak, W. Vortex-Induced Formation of Insulin Amyloid Superstructures Probed by Time-Lapse Atomic Force Microscopy and Circular Dichroism Spectroscopy. J. Mol. Biol., 2010, 395, 643-655.
34. Loksztejn, A.; Dzwolak, W. Chiral bifurcation in aggregating insulin: an induced circular dichroism study. J. Mol. Biol., 2008, 379, 9-16.
35. Sadhale, Y.; Shah, J.C. Stabilization of insulin against agitationinduced aggregation by the GMO cubic phase gel. Intl. J. Pharm., 1999, 191, 51-64.
36. Rasmussen T.; Tantipolphan R.; van de Weert M.; Jiskoot W. The molecular chaperone α-crystallin as an excipient in an insulin formulation. Pharm. Res., 2010, 27, 1337-1347.
37. Zhang, N.; Li, J.; Jiang, W.; Ren, C.; Li, J.; Xin, J.; Li, K. Effective protection and controlled release of insulin by cationic β- cyclodextrin polymers from alginate/chitosan nanoparticles. Inter. J. Pharmaceutics, 2010, 393, 212-218.
38. Junyan A. J.; Liu, J.; Shire, S. J.; Kamerzell, T. J.; Hong, S.; Billeci, K.; Shen, Y.; Wang, Y. J. Characteristic of rhVEGF release from topical Hydrogel formulations. Pharm. Res., 2010, 27, 644-655.
39. Graber S.E.; Krantz S.B. Erythropoietin and control of red-cell production. Annu. Rev. Med., 1978, 29, 51-66.
40. Deechongkit, S.; Aoki, K.H.; Park, S.S.; Kerwin, B.K. Biophysical comparability of the same protein from different manufactures: a casa study using Epoetin alfa from Epogen and Eprex. J. Pharm. Sci., 2006, 95, 1931-1943.
41. Arvinte T.; Drake A.F. Comparative study of human and salmon calcitonin secondary structure in solutions with low dielectric constants. J. Biol. Chem., 1993, 268, 6408-6414.
42. Konno S.; Fenton J.W.; Villanueva G.B.; Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin. Arch. Biochem. Biophys., 1988, 267, 158-166.
43. Cindrić M.; Galić N.; Vuletić M.; Klarić M.; Drevenkar V. Evaluation of recombinant human interferon α-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J. Pharm. Biomed. Anal., 2006, 40, 781-787.
44. Grace M.; Youngster S.; Gitlin G.; Sydor W.; Xie L.; Westreich L.; Jacobs S.; Brassard D.; Baush J.; Bordens R. Structural and biological characterization of pegylated recombinant interferon - α2b. J. interferon Cytokine Res., 2001, 21, 1103-1115.
45. Wang Y.S.; Youngster S.; Grace M.; Bausch J.; Bordens R.; Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev., 2002, 54, 547-570.
46. Taschner N.; Müller S.A.; Alumella V.R.; Goldie K.N.; Drake A.F.; Aebi U.; Arvinte T. Modulation of antigenicity related to changes in antibody flexibility upon lyophilisation. J. Mol. Biol., 2001, 310, 169-179.
47. Weiss, A.; Preston, T.C.; Popov, J.; Li, Q.; Wu, S.; Chou, K.C.; Burt, H.M.; Bally, M.B.; Signorell, R. Selective Recognition of Rituximab- Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging. J. PhysChem. C, 2009, 113, 20252-20258.
48. Liu, S.; Lu, H.; Niu, J.; Xu, Y.; Wu, S.; Jiang, S. Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120. J. Biol. Chem., 2005, 280, 11259-11273.
49. Kelly, S.M.; Jess, T.J.; Price, N.C. How to study proteins by circular dichroism. Biochim. Biophys. Acta, 2005, 1751, 119-138.
50. Hughes, H.; Morgan, C.; Brunyak, E.; Barranco, K.; Cohen, E.; Edmunds, T.; Lee, K. A multi-tiered analytical approach for the analysis and quantitation of high-molecular-weight aggregates in a recombinant therapeutic glycoprotein. AAPS J., 2009, 11, 335-341.